Akihiro Ginnaga

Kumamoto, 8608568, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan. Part I. Venom Extraction, Preparation, and Laboratory Testing.

Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan. Part I. Venom Extraction, Preparation, and Laboratory Testing.

Journal: Japanese journal of infectious diseases

Published: March 02, 2018

Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan. Part II. Experimental Production of Equine Antivenom against the Redback Spider.

Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan. Part II. Experimental Production of Equine Antivenom against the Redback Spider.

Journal: Japanese journal of infectious diseases

Published: November 03, 2017

Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.

Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.

Journal: Japanese journal of infectious diseases

Published: March 03, 2017

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan.

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: September 07, 2015

Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.

Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.

Journal: Basic & clinical pharmacology & toxicology

Published: April 09, 2014

Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.

Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: April 07, 2014

Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.

Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.

Journal: Frontiers in neurology

Published: February 10, 2014

Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.

Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: September 30, 2013

Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.

Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: April 12, 2013

Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.

Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: December 15, 2012

Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Journal: The Journal of physiology

Published: October 31, 2012

Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons.

Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons.

Journal: Journal of pharmacological sciences

Published: December 14, 2011

Showing 1-12 of 14

Last Updated: 09/26/2026